Health & Wellness | 健康知识库

by 大牙哥

肽类疗法对身心健康的益处与风险

Benefits & Risks of Peptide Therapeutics for Physical & Mental Health

15分钟阅读

肽类疗法对身心健康的益处与风险

摘要

本期节目全面概述了目前用于组织修复、代谢与生长、长寿以及改善情绪与性欲的治疗性肽类物质。Andrew Huberman 阐释了肽类物质的生物学作用机制，将其分类整理，并概述了使用这些物质的潜在益处与重大风险。节目特别强调，应通过经委员会认证的医生和持牌复合制剂药房来安全获取肽类物质。

核心要点

  • 肽是由2至100个氨基酸组成的小蛋白质，具有广泛的或称多效性效应——它们几乎从不只发挥单一作用
  • 存在三个来源层级：FDA批准的处方肽（最安全）、灰市肽（质量参差不齐）以及黑市肽（因含lipopolysaccharide即LPS等污染物风险，应完全避免）
  • BPC-157 在动物实验中显示出通过angiogenesis（血管生成）和成纤维细胞迁移促进组织修复的有力证据，但因其上调VEGF，存在真实的肿瘤生长风险
  • 生长激素促泌素（第1类：Sermorelin、Tesamorelin；第2类：Ipamorelin、Hexarelin）可提升growth hormone（生长激素）和IGF-1水平，但存在包括促进肿瘤、受体脱敏和睡眠紊乱在内的风险
  • Epithalon 是主要的抗衰老肽类物质，被认为可恢复端粒长度并调节昼夜节律/褪黑素模式——但人体临床试验数据基本缺失
  • Melanotan 肽类物质及 PT-141（Bremelanotide） 通过激活melanocortin system（黑皮质素系统）来提升性欲、改善情绪并促进皮肤色素沉着——PT-141 已获FDA批准用于治疗绝经前女性性欲减退障碍
  • 时机至关重要：大多数生长激素肽类物质应在餐后1.5至2小时服用，并于夜间使用，以配合机体在睡眠期间的自然生长激素脉冲分泌规律
  • 已知有肿瘤或癌症的人应避免使用BPC-157和growth hormone促泌素，因为两者均可加速肿瘤生长

详细笔记

什么是肽？

  • 肽是由2至约100个氨基酸排列成链状结构的小蛋白质
  • 多个肽组合形成多肽，进而构成体内众多蛋白质
  • 常见的天然肽包括insulin（胰岛素）和oxytocin（催产素）
  • 大多数肽具有多效性效应——可同时激活多条细胞信号通路，根据情境、剂量和时机的不同，对不同组织产生影响
  • 这使得预测效果和副作用变得复杂；针对单一效应的靶向肽疗法十分罕见

来源与安全性

  • 处方肽（FDA批准，来自制药公司或复合制剂药房）：最安全——制造过程中已去除LPS
  • 灰市肽：可在网上购买；通常未经LPS去除处理；纯度参差不齐
  • 黑市肽：污染风险极高；标签内容可能与实际成分不符——强烈不建议使用
  • 制造过程中的**lipopolysaccharide（LPS）**污染可引发累积性免疫反应，使用前必须去除
  • 强烈建议任何考虑使用治疗性肽类物质的人，务必与经委员会认证的医生合作

第一类：组织再生与修复

BPC-157（身体保护复合物）

  • 天然来源于胃液；合成形式为BPC-157
  • 作用机制：通过上调VEGF和eNOS（内皮型一氧化氮合酶）促进angiogenesis（血管生成）；促进成纤维细胞迁移；增加损伤部位生长激素受体的表达
  • 动物实验证据：在坐骨神经、跟腱和韧带修复方面有大量数据支持——包括大鼠完全横断后的恢复案例
  • 人体证据：主要为个案报告；尚无严格的临床试验
  • 典型剂量：300至500微克，皮下注射或肌肉注射，每周2至5次，持续约8周；随后停用8至10周
  • 风险：
    • 刺激VEGF → 促进肿瘤血管化（与Avastin等抑制VEGF的抗癌药物效果相反）
    • 已知患有癌症、肿瘤或涉及异常血管生长的眼部疾病（如湿性年龄相关性黄斑变性）的患者应避免使用
    • 全身注射与局部注射哪种方式更有效，目前尚无定论

Thymosin Beta-4 / TB-500

  • 儿童时期由胸腺自然分泌；与青少年时期伤口愈合更快、疤痕更少有关
  • TB-500 是 Thymosin Beta-4 的截短型实验室合成版本，具有相似但略有不同的作用，且作用持续时间更长
  • 作用机制：促进干细胞增殖、细胞外基质生长，以及与伤口修复相关的多种细胞类型的迁移
  • 不会显著影响growth hormone（生长激素）通路
  • 常与BPC-157联合使用
  • 证据基础：主要为动物研究；有人体个案报告

第二类：代谢与生长（生长激素促泌素）

生长激素背景知识

  • 由垂体前叶分泌，受下丘脑分泌的促生长激素释放激素（GHRH）刺激
  • 自然分泌高峰出现在睡眠初期；30岁后每十年下降约15%
  • 刺激肝脏产生IGF-1，驱动组织生长、代谢效率提升和能量（ATP）生成
  • 直接使用外源性生长激素会产生负反馈，抑制机体自身的生长激素分泌

第1类肽（GHRH模拟物）

这类物质模拟促生长激素释放激素，直接刺激垂体。

  • Sermorelin

    • 已获FDA批准用于矮小症；超说明书用于生长激素补充
    • 剂量：每晚200至400微克，每周3至5次
    • 可增加深度（慢波）睡眠；可能减少REM sleep（快速眼动睡眠）——Huberman提到本人因此效应而停止使用
    • 与第2类肽相比，受体脱敏风险较低

  • Tesamorelin（Egrifta）

    • 已获FDA批准用于HIV患者的内脏脂肪增多症
    • 作用持续时间比Sermorelin更长；通常每周使用约3次
    • 减少内脏脂肪；益处与Sermorelin相似

  • CJC-1295

    • 含有药物亲和复合物（DAC），使其作用时间极长；每周给药1至2次
    • 临床试验中曾有1例死亡（心血管事件——可能与液体潴留有关）
    • 在Sermorelin或Tesamorelin可作为更安全替代品的情况下，不推荐使用

第2类肽（Ghrelin模拟物）

这类物质模拟ghrelin（饥饿素），通过独立的受体通路刺激生长激素释放，副作用包括增加饥饿感和焦虑感。

  • Ipamorelin

    • 直接增加生长激素分泌，并抑制生长抑素（生长激素释放的”刹车”）
    • 改善深度睡眠；饥饿感和焦虑感副作用比其他第2类药物更轻微

  • Hexarelin

    • 最强效的生长激素刺激物（分泌脉冲是其他促泌素的2至3倍）
    • 主要风险：可导致受体脱敏/内化——可能永久性关闭GHRH受体通路
    • 升高催乳素（抑制性欲）、引起液体潴留和不适感

  • GHRP-2、GHRP-3、GHRP-6

    • 强效生长激素刺激物；会显著升高**cortisol**（皮质醇，升幅超过2倍）——在cortisol本应处于低水平的傍晚使用时尤为不妥

  • MK-677

    • 口服（非注射）Ghrelin模拟物
    • 与其他第2类肽风险特征相同：皮质醇和催乳素升高

生长激素的一般风险

  • 无差别促进组织生长 → 加速肿瘤生长
  • 长期使用可导致身体变化：腕管综合征、关节改变、面部骨骼增厚、腹部膨出（“GH肚”）
  • 与BPC-157联合使用

English Original 英文原文

Benefits & Risks of Peptide Therapeutics for Physical & Mental Health

Summary

This episode provides a comprehensive overview of therapeutic peptides currently in use for tissue repair, metabolism and growth, longevity, and mood and libido enhancement. Andrew Huberman explains the biology of how peptides work, organizes them into clear categories, and outlines both the potential benefits and significant risks associated with their use. A strong emphasis is placed on sourcing peptides safely through board-certified physicians and licensed compounding pharmacies.

Key Takeaways

  • Peptides are small proteins (2–100 amino acids) with wide-ranging, or pleiotropic, effects — they almost never do just one thing
  • Three sourcing tiers exist: FDA-approved prescription peptides (safest), gray-market peptides (variable quality), and black-market peptides (avoid entirely due to contamination risks including lipopolysaccharide or LPS)
  • BPC-157 shows strong animal evidence for tissue repair via angiogenesis and fibroblast migration, but carries real tumor-growth risk due to VEGF upregulation
  • Growth hormone secretagogues (Type 1: Sermorelin, Tesamorelin; Type 2: Ipamorelin, Hexarelin) can increase growth hormone and IGF-1, but carry risks including tumor promotion, receptor desensitization, and sleep disruption
  • Epithalon is the primary longevity-focused peptide, thought to restore telomere length and regulate circadian/melatonin patterns — but human clinical trial data are largely absent
  • Melanotan peptides and PT-141 (Bremelanotide) activate the melanocortin system to increase libido, mood, and skin pigmentation — PT-141 is FDA-approved for premenopausal hypoactive sexual desire disorder
  • Timing matters: Most growth hormone peptides should be taken 1.5–2 hours after eating and at night to align with the body’s natural GH pulse during sleep
  • Anyone with known tumors or cancer should avoid BPC-157 and growth hormone secretagogues, as both can accelerate tumor growth

Detailed Notes

What Is a Peptide?

  • A peptide is a small protein composed of 2 to ~100 amino acids arranged in a chain
  • Combining peptides creates polypeptides, which form many proteins in the body
  • Well-known natural peptides include insulin and oxytocin
  • Most peptides have pleiotropic effects — they activate multiple cell pathways simultaneously, affecting different tissues depending on context, dose, and timing
  • This makes predicting effects and side effects complex; targeted single-effect peptide therapy is rare

Sourcing and Safety

  • Prescription peptides (FDA-approved, from pharma or compounding pharmacies): Safest — LPS is removed during manufacturing
  • Gray-market peptides: Can be purchased online; often lack LPS removal; variable purity
  • Black-market peptides: High contamination risk; labels may not match contents — strongly discouraged
  • Lipopolysaccharide (LPS) contamination from manufacturing can trigger cumulative immune responses and must be removed before use
  • Working with a board-certified physician is strongly recommended for anyone considering therapeutic peptides

Category 1: Tissue Rejuvenation and Repair

BPC-157 (Body Protection Compound)

  • Naturally derived from gastric juice; synthesized as BPC-157
  • Mechanism: Promotes angiogenesis via upregulation of VEGF and eNOS (endothelial nitric oxide synthase); encourages fibroblast migration; increases growth hormone receptor expression at injury sites
  • Animal evidence: Robust data on sciatic nerve, Achilles tendon, and ligament repair — including complete transection recovery in rats
  • Human evidence: Largely anecdotal; no rigorous clinical trials
  • Typical dosage: 300–500 micrograms, subcutaneously or intramuscularly, 2–5x per week for ~8 weeks; cycle off for 8–10 weeks
  • Risks:
    • Stimulates VEGF → promotes tumor vascularization (opposite of anti-cancer drugs like Avastin, which inhibit VEGF)
    • People with known cancer, tumors, or eye diseases involving abnormal vessel growth (e.g., wet AMD) should avoid it
    • Whether systemic vs. local injection is more effective remains unresolved

Thymosin Beta-4 / TB-500

  • Naturally secreted by the thymus in children; associated with faster wound healing and minimal scarring in youth
  • TB-500 is a truncated, lab-synthesized version of Thymosin Beta-4 with similar but slightly different action and longer duration
  • Mechanism: Promotes stem cell proliferation, extracellular matrix growth, and migration of multiple cell types associated with wound repair
  • Does not significantly impact the growth hormone pathway
  • Commonly stacked with BPC-157
  • Evidence base: Primarily animal studies; anecdotal human reports

Category 2: Metabolism and Growth (Growth Hormone Secretagogues)

Background on Growth Hormone

  • Secreted by the anterior pituitary, stimulated by growth hormone–releasing hormone (GHRH) from the hypothalamus
  • Naturally peaks during the early phase of sleep; declines ~15% per decade after age 30
  • Stimulates the liver to produce IGF-1, which drives tissue growth, metabolic efficiency, and energy production (ATP)
  • Taking exogenous growth hormone directly creates negative feedback, suppressing the body’s own production

Type 1 Peptides (GHRH Mimetics)

These mimic growth hormone–releasing hormone and stimulate the pituitary directly.

  • Sermorelin

    • FDA-approved for short stature; used off-label for GH augmentation
    • Dosage: 200–400 mcg at night, 3–5x per week
    • Increases deep (slow-wave) sleep; may reduce REM sleep — Huberman noted personally stopping due to this effect
    • Lower desensitization risk than Type 2 peptides

  • Tesamorelin (Egrifta)

    • FDA-approved for visceral adiposity in HIV patients
    • Longer-lasting than Sermorelin; typically taken ~3x per week
    • Reduces visceral fat; similar benefits to Sermorelin

  • CJC-1295

    • Contains a Drug Affinity Complex (DAC) making it very long-lasting; dosed 1–2x per week
    • One death occurred in clinical trials (cardiovascular event — possibly related to fluid retention)
    • Not recommended when Sermorelin or Tesamorelin are available as safer alternatives

Type 2 Peptides (Ghrelin Mimetics)

These mimic ghrelin, stimulating GH release through a separate receptor pathway. They also increase hunger and anxiety as side effects.

  • Ipamorelin

    • Increases GH directly and suppresses somatostatin (the brake on GH release)
    • Improves deep sleep; hunger and anxiety side effects milder than other Type 2 options

  • Hexarelin

    • Most potent GH stimulator (2–3x the pulse of other secretagogues)
    • Major risk: Can cause receptor desensitization/internalization — potentially permanently shutting down the GHRH receptor pathway
    • Raises prolactin (suppresses libido), causes fluid retention and malaise

  • GHRP-2, GHRP-3, GHRP-6

    • Potent GH stimulators; significantly raise cortisol (>2x) — problematic for evening use when cortisol should be low

  • MK-677

    • Oral (non-injectable) ghrelin mimetic
    • Same risk profile as other Type 2 peptides: elevated cortisol and prolactin

General Growth Hormone Risks

  • Indiscriminate tissue growth → accelerates tumor growth
  • Physical changes with prolonged use: carpal tunnel, joint changes, facial bone thickening, distended abdomen (“GH gut”)
  • Combining BPC-157

关系图谱